tacrolimus topical / Generic mfg. - LARVOL DELTA

NALFURAFINE FOR REFRACTORY UREMIC AND CHOLESTATIC PRURITUS IN A HEMODIALYSIS PATIENT: A CASE REPORT (ISN-WCN 2026) - "During her course, she experienced recurrent spontaneous bacterial peritonitis (pathogen: vancomycin-resistant Enterococcus faecium) necessitating multiple courses of broad-spectrum antibiotics (including cefoperazone-sulbactam, meropenem, daptomycin, linezolid)...Initially suspected as a drug allergy, all potential culprit medications were discontinued, and prednisone was administered...Despite trials of various standard therapies including antihistamines, intensified hemodialysis with hemoperfusion, gabapentin, ursodeoxycholic acid, sertraline, topical tacrolimus ointment, and achieving targets for phosphate and parathyroid hormone control, the generalized pruritus remained refractory...This outcome underscores its mechanistic advantage and potential therapeutic value in challenging clinical scenarios involving mixed-origin pruritus.Conclusion In conclusion, nalfurafine presents a promising therapeutic option for refractory pruritus of mixed uremic and cholestatic..."

Case report • Clinical • Chronic Kidney Disease • Dermatology • Fibrosis • Hepatology • Immunology • Infectious Disease • Inflammation • Liver Cirrhosis • Liver Failure • Nephrology • Pruritus • Renal Disease • Urticaria

Health Insurance Coverage of Topical Medications in Vitiligo and Atopic Dermatitis (AAD 2026) - "Given limited coverage of topical tacrolimus and narrowband UVB phototherapy described prior to ruxolitinib approval, we performed cross-sectional analysis of topical ruxolitinib coverage versus other first-line agents in vitiligo with atopic dermatitis (AD) for comparison...Of 80 commercial insurance organizations and seven Medicaid programs, 57/87 (65.5%) covered ruxolitinib 1.5% cream, 82/87 (94.3%) covered tacrolimus 0.03% ointment, and 87/87 (100%) covered triamcinolone 0.1% ointment for vitiligo (p<0.001), compared to 57/87 (65.5%), 87/87 (100%), and 87/87 (100%), respectively, for AD (p<0.001), a statistically significant difference in coverage between drug types for both diseases...For plans with coverage, the median number of stipulations for coverage for vitiligo was three for ruxolitinib, two for tacrolimus, and none for triamcinolone (p<0.0001, Kruskal-Wallis). Though ruxolitinib is the only FDA-approved therapeutic for vitiligo, it remains less..."

Reimbursement • US reimbursement • Atopic Dermatitis • Dermatitis • Dermatology • Immunology • Vitiligo

Refractory nasal pemphigus vegetans treated with dupilumab in a patient with multiple contraindications to first-line therapies (AAD 2026) - "Management was complicated by steroid-induced hyperglycemia, dapsone-associated methemoglobinemia, thiopurine methyltransferase deficiency, and a rituximab biosimilar infusion reaction...Based on emerging data on dupilumab’s use towards remission induction in refractory pemphigus vulgaris, we initiated dupilumab 300mg every 4 weeks combined with low-dose mycophenolate mofetil...Treatment was discontinued due to persistent gastrointestinal discomfort, and nasal lesions recurred 13 weeks later despite the use of topical tacrolimus 0.01% ointment and clobetasol 0.05% ointment twice daily. Although prior data on dupilumab for pemphigus vegetans is lacking, dupilumab may represent a steroid-sparing option for pemphigus vegetans in patients who cannot tolerate rituximab or its biosimilars. Prospective research should evaluate dupilumab’s efficacy in achieving and maintaining pemphigus vegetans remission."

Clinical • Bullous Pemphigoid • Chronic Rhinosinusitis With Nasal Polyps • Dermatopathology • Diabetes • Gastrointestinal Disorder • Hematological Disorders • Immunology • Metabolic Disorders • Nasal Polyps • Otorhinolaryngology • Pemphigus Vulgaris • Respiratory Diseases • Sinusitis • Type 2 Diabetes Mellitus

308-nm excimer laser (EL) plus tacrolimus significantly enhances repigmentation compared to EL monotherapy in vitiligo: A systematic review and meta-analysis (AAD 2026) - "Combining the 308-nm excimer laser (EL) with topical tacrolimus 0.1% offers a dual approach that may enhance repigmentation, yet its true efficacy remains uncertain...Our findings suggest that combining the excimer laser with 0.1% tacrolimus is more effective than monotherapy for achieving repigmentation in vitiligo, particularly in older adults and patients with localized, treatment-resistant lesions, while maintaining a favorable safety profile. This study provides the first high-level evidence supporting this combination as a clinically significant and evidence-based treatment option."

Monotherapy • Retrospective data • Review • Dermatology • Immunology • Vitiligo

Balanitis Xerotica Obliterans Successfully Treated with Topical Tacrolimus: A Case Report and Literature Review. (PubMed, Clin Cosmet Investig Dermatol) - "No side effects were observed. Our findings are consistent with published data and further support the recommendation for topical tacrolimus as a therapeutic option for BXO."

Journal • Dermatology • Pain • Pruritus • Sexual Disorders

Pediatric Pigmented Lichen Planus: A Rare Case and Therapeutic Challenge (AAD 2026) - "Treatment with systemic betamethasone (0.2 mg/kg/day tapered over two weeks) and topical tacrolimus 0.1% resulted in significant clinical improvement and stabilization of new lesions...PLP in children is an exceptional entity that should be considered in the evaluation of pediatric hyperpigmentation. This report contributes to the limited body of evidence and supports combined therapeutic approaches for its management."

Clinical • Dermatitis • Dermatology • Dermatopathology • Immunology • Infectious Disease • Lichen Planus • Pediatrics

Partial Re-pigmentation of Discoid Lupus Scars with Anifrolumab in Patient with Skin of Color (AAD 2026) - "A 50-year-old male active smoker, Fitzpatrick V, known for longstanding systemic lupus erythematosus (diagnosed in 2010) and generalized discoid lupus erythematosus (beginning in 2014) presented to follow up at the dermatology clinic after his SLE treatment had been modified from belimumab to anifrolumab by rheumatology 5 months prior. He was also on hydroxychloroquine and had previously been treated with methotrexate followed by mycophenolate mofetil which resulted in partial improvement of his skin disease. Additionally, his DLE lesions, which affected the scalp, cheeks, upper arms, and lateral chest bilaterally, were treated with Kenalog injections and various topical medications (protopic, dermovate, diprolene, elocom)...At follow up, new peripheral and inward progression of pigment on the lesions was noted, as well as improvement in disease activity with absence of erythema, which was confirmed with comparison to previous photographs. He denied any new lesions on..."

Clinical • Discoid Lupus Erythematosus • Immunology • Inflammatory Arthritis • Lupus • Systemic Lupus Erythematosus

It's Not a Tumor? Lessons Learned from Interesting Cases (USCAP 2026) - "Due to breastfeeding, she was treated with topical tacrolimus and hydrocortisone with intermittent recovery, followed by injectable steroids for approximately one year, with which she had significant improvement...She was concurrently started on prednisone and had remarkable clinical improvement...Serology for ANA, p-ANCA, c-ANCA, SS-A/Ro and SS-B/LA antibodies resulted negative. Figure 1 Virtual Slide: https://uscap.org/EC14-26-03_Vizcaino_H&E"

Clinical • Asthma • Atopic Dermatitis • Dermatitis • Immunology • Inflammation • Mood Disorders • Oncology • Ophthalmology • Respiratory Diseases

Case Report: Lupus miliaris disseminatus faciei successfully treated with thalidomide combined with photodynamic therapy: two cases and literature review. (PubMed, Front Immunol) - "Here, we report two young male patients with LMDF presenting with multiple firm red papules on the face, both of whom had previously received four lines of treatment-including antibiotics (minocycline, doxycycline, clarithromycin), topical tacrolimus, and traditional Chinese medicine-without clinical improvement. These cases suggest that PDT combined with thalidomide may provide an effective option for refractory LMDF, with early intervention potentially minimizing scarring. Further studies and controlled trials are warranted to confirm the efficacy and safety of this therapeutic approach."

Journal • Review • Dermatology • Immunology • Inflammatory Arthritis • Lupus • Rosacea

FEATURES OF PATIENTS WITH MORPHEA: A SINGLE CENTER 15-YEAR EXPERIENCE (SSWC 2026) - "Treatment included mainly topical tacrolimus or steroids (in 65.4% of patients) whereas systemic agents, such as methotrexate, hydroxychloroquine, steroids and cyclosporine (in 38.6% of patients), were reserved for extensive disease. This is the first study to assess morphea features in Greece and our findings align with international data. The high frequency of autoimmune comorbidity underscores the shared autoimmune background of morphea. Malignancies presented in 11.1% of patients highlighting the need for careful long-term follow-up."

Clinical • Colon Cancer • Colorectal Cancer • Crohn's disease • Diabetes • Endocrine Disorders • Gastroenterology • Hypertension • Immunology • Inflammatory Bowel Disease • Melanoma • Metabolic Disorders • Musculoskeletal Pain • Scleroderma • Sjogren's Syndrome • Solid Tumor • Systemic Sclerosis • Thyroid Gland Carcinoma • Type 1 Diabetes Mellitus • Type 2 Diabetes Mellitus

A Case of Porokeratosis Ptychotropica Treated with Cryotherapy. (PubMed, Acta Dermatovenerol Croat) - "Therapeutic options are controversial and include topical corticosteroids, topical tacrolimus, PUVA, systemic retinoids, imiquimod, 5-fluorouracil, CO2 or excimer laser therapy, and cryotherapy2,4. We report an extremely rare case of porokeratosis ptychotropica affecting a female patient. This case is also unique due to the successful treatment of the lesions with cryotherapy; further case series using this treatment option may validate it as an acceptable standard treatment for small lesions of porokeratosis ptychotropica."

Journal • Dermatitis • Dermatology • Dermatopathology • Immunology • Infectious Disease • Lichen Planus • Oncology • Pruritus • Psoriasis • Pulmonary Disease • Respiratory Diseases • Squamous Cell Carcinoma • Tuberculosis

Efficacy of Oral JAK Inhibitors Combined with 308-nm Excimer Laser in Pediatric Progressive Vitiligo: A Multicenter Study. (PubMed, J Am Acad Dermatol) - "JAK inhibitor combined with 308-nm excimer laser therapy demonstrates promising efficacy and safety in pediatric progressive vitiligo, supporting its potential as a therapeutic option."

Clinical • Journal • Dermatology • Immunology • Pediatrics • Vitiligo

Comparative Evaluation of the Safety and Effectiveness of Crisaborole Ointment (2%) Versus Tacrolimus Ointment (0.1%) for the Topical Treatment of Atopic Dermatitis (clinicaltrials.gov) - P4 | N=148 | Not yet recruiting | Sponsor: Hayat Abad Medical Complex, Peshawar

New P4 trial • Atopic Dermatitis • Dermatitis • Dermatology • Immunology

Successful treatment of nodular scabies with long-lasting ivermectin dose schedule in an adult patient non responder to permethrin. (PubMed, IDCases) - "Given the non-response, the decision was made to start ivermectin along with tacrolimus ointment...Nodular lesions gradually disappeared leaving hyperchromic lesions occasional flared up with burning sensation and were treated on demand with topic aloe. This report suggests that a personalized and long-term ivermectin schedule can be successful in selected cases of nodular scabies with previous resistance to permethrin."

Journal • Dermatology • Infectious Disease • Pruritus

Clinical outcomes and Th17-associated immunomodulation in vitiligo treated with tacrolimus ointment plus narrow-band ultraviolet light. (PubMed, Pak J Pharm Sci) - "Tacrolimus plus NB-UVB is more effective than tacrolimus alone for vitiligo, reducing lesion size and disease activity, down regulating Th17-associated immunity and improving systemic immune profile."

Clinical data • Journal • CNS Disorders • Depression • Dermatology • Immunology • Mood Disorders • Psychiatry • Vitiligo • IL17A • IL22

A systematic review of treatment strategies to combat acute and chronic rejection episodes in vascularized composite allotransplantation. (PubMed, Front Immunol) - "Corticosteroids were the mainstay (n=98; 72%)-methylprednisolone (n=31; 23%), clobetasol (n=15; 11%), and prednisone (n=11; 8.1%); tacrolimus was used in 49 (36%), including topical in 29 (21%). Other immunosuppressants included antithymocyte globulin (n=19; 14%), alemtuzumab (n=11; 8.1%), mycophenolate mofetil (n=11; 8.1%), and rituximab (n=6; 4.4%); basiliximab (n=4; 2.9%), sirolimus (n=2; 1.5%), and plasmapheresis (n=4; 2.9%) were used selectively. Monotherapy was used in 42 episodes, and dual therapy in 51, most commonly methylprednisolone plus topical tacrolimus (n=26). This review underscores the ongoing challenge of rejection in VCA and the need for improved treatment strategies, with corticosteroids, calcineurin inhibitors, and mycophenolate mofetil remaining standard while emerging biologicals offer promise. Acute rejection is often manageable yet threatens graft survival, whereas chronic rejection is less reported, likely under-recognized and harder to treat,..."

Journal • Review • Dermatology • Immunology • Solid Organ Transplantation • Transplant Rejection • Transplantation

Fibroblast-derived small extracellular vesicles loaded with tacrolimus enhances dermal delivery and alleviates cytokine-overdriven skin inflammation. (PubMed, Drug Deliv Transl Res) - "Topical tacrolimus, a calcineurin inhibitor, is commonly used to manage such conditions due to its immunosuppressive properties...PKH-26 fluorescence labelling confirmed efficient cellular uptake, while cytotoxicity assays (Alamar Blue, CCK-8) showed high cell viability for both formulations. In summary, these results position Tac-sEVs as a safe and promising therapeutic platform for cytokine-driven inflammatory skin diseases associated with long COVID, meriting further clinical investigation."

Journal • Dermatitis • Dermatology • Infectious Disease • Inflammation • Novel Coronavirus Disease • Respiratory Diseases • IFNG • IL2 • IL4

Efficacy and safety of treatments for atopic dermatitis: a model based meta-analysis of randomized controlled trials. (PubMed, Eur J Clin Pharmacol) - "MBMA was conducted for the time courses of several efficacy index. In conclusion, results showed that there is still a lack of treatment methods that balance efficacy, safety and speed of onset. The results of this MBMA can be used as a reference for optimizing clinical medication and provide a basis for decision-making in the future development of new AD drugs."

Clinical • Journal • Retrospective data • Review • Atopic Dermatitis • Dermatitis • Dermatology • Immunology • Pruritus

Tacrolimus attenuates Th17 cell-mediated allergic skin inflammation in mice. (PubMed, J Pharmacol Sci) - "Tacrolimus, a topical calcineurin inhibitor, is used to treat atopic dermatitis (AD)...In Th17-transferred mice, tacrolimus significantly reduced allergen-specific T-cell accumulation in OVA-injected skin and tended to reduce Il21 expression, whereas Th2-cell accumulation and cytokine expression were unaffected. Tacrolimus exerts stronger inhibitory effects on Th17- than Th2-driven responses in this model, suggesting that suppression of Th17 pathways may contribute to its therapeutic benefit in AD."

IO biomarker • Journal • Preclinical • Atopic Dermatitis • Dermatitis • Dermatology • Immunology • Inflammation • CD4 • IL17A • IL21 • IL22

Topical Tacrolimus 0.1% in the Treatment of Thygeson's Superficial Punctate Keratitis. (PubMed, Cureus) - "This case highlights the potential of non-ophthalmic tacrolimus 0.1% ointment, a higher-concentration formulation not previously described in the TSPK literature, as an effective therapeutic option that may contribute to prolonged symptom control while avoiding the intraocular pressure risks associated with steroid use, particularly in young patients. Tacrolimus may represent a promising alternative therapy for patients requiring chronic management of TSPK."

Journal • Keratitis • Ocular Inflammation • Ophthalmology

The evidence-based indications of 0.1% topical tacrolimus in ophthalmology: a scoping review. (PubMed, Ther Adv Ophthalmol) - "0.1% tacrolimus is effective and safe for a wide spectrum of eye diseases involving the anterior segment and adnexa. Not only does 0.1% topical tacrolimus spare patients from the side effects of chronic topical corticosteroid use but it also emerges as an option for patients inadequately managed by other immunosuppressants, highlighting the growing significance of 0.1% tacrolimus in ophthalmic practice."

Journal • Conjunctivitis • Dermatitis • Dermatology • Dry Eye Disease • Graft versus Host Disease • Immunology • Inflammation • Keratitis • Ocular Infections • Ocular Inflammation • Oncology • Ophthalmology • Scleritis • Transplant Rejection • Transplantation

Topical Cyclosporine Vs Tacrolimus for Ocular GVHD Prophylaxis after Allogeneic Hematopoietic Stem Cell Transplantation: A Phase I–II Trial (TCT-ASTCT-CIBMTR 2026) - P1/2 | "This study evaluated the safety, tolerability, and early efficacy of topical tacrolimus (Tac) versus cyclosporine (Cys) for oGVHD prevention in the outpatient alloHCT setting...Systemic GVHD prophylaxis included post-transplant cyclophosphamide, a calcineurin inhibitor, and mycophenolate... Both topical Tac and Cys were safe, well tolerated, and associated with high adherence in outpatient alloHCT. Tac showed a trend toward fewer dry eye symptoms and lower ocular toxicity, though not statistically significant. Ocular QoL remained preserved in both groups, supporting the feasibility of topical immunomodulator prophylaxis for oGVHD."

P1/2 data • Acute Graft versus Host Disease • Bone Marrow Transplantation • Dermatology • Dry Eye Disease • Graft versus Host Disease • Immunology • Infectious Disease • Ocular Infections • Ophthalmology • Pruritus • Transplantation

A bilayered microneedle patch loaded with methotrexate and dexamethasone for transdermal treatment of psoriasis. (PubMed, Sci Rep) - "The patch successfully traversed imiquimod (IMQ)-induced thickened epidermis in murine models to achieve intralesional drug delivery and effectively alleviate psoriasis-like skin inflammation. Versus tacrolimus ointment (positive control), MTX@DXM-MNs markedly alleviated the manifestations of stratum corneum thickening, erythema, and scaling in a mouse model and attenuated the levels of inflammatory mediators in skin tissues and peripheral blood as well as splenic indices. In conclusion, the MTX@DXM-MN bilayered microneedle patch provides a new strategy for the efficient and safe treatment of psoriasis through the temporal and spatial synergistic effects of an outer layer for the immediate release of a hormone and an inner layer for the slow release of an immunosuppressant. Thus, this patch has potential as a future clinical alternative for the treatment of psoriasis."

Journal • Dermatitis • Dermatology • Immunology • Inflammation • Psoriasis

Long-Term Clinical Outcomes of 0.015% Tacrolimus HPβCD Eye Drops in Ocular Surface Inflammatory Disorders. (PubMed, Eur J Pharm Sci) - "The 0.015% tacrolimus/HPβCD formulation proves efficacy, and safety over 12 months for the treatment of diverse ocular inflammatory conditions, delivering sustained clinical stability and patient-reported benefits with reduced steroid reliance."

Clinical data • Journal • Inflammation • Ocular Inflammation • Ophthalmology

A preclinical study of device dependent therapeutic effects of cold atmospheric plasmas on atopic dermatitis induced by DNCB. (PubMed, Sci Rep) - "Mice were treated with cold plasma and tacrolimus ointment (TAC)...Additionally, helium and argon plasma treatment enhanced cell adhesion protein E-cadherin and modulated CD31 protein, a marker of angiogenesis. Together, these findings suggest that CAP may be a promising candidate for the research and development of therapeutic modalities for AD."

Journal • Preclinical • Atopic Dermatitis • Dermatitis • Dermatology • Immunology • Inflammation • CD31 • CDH1 • IL12A • IL13 • PECAM1